Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma
Completed · Phase 3
Conditions studied: Intraocular Retinoblastoma
In brief
This phase III trial is studying how well giving carboplatin and vincristine together with standard local ophthalmic therapy works in treating children with intraocular retinoblastoma. Drugs used in chemotherapy, such as carboplatin and vincristine, work in different ways to stop tumor from dividing so they stop growing or die. It is not yet known whether neoadjuvant chemotherapy combined with standard local ophthalmic therapy is effective in treating intraocular retinoblastoma.
Key facts
- Study ID
- NCT00079417
- Run by
- Children's Oncology Group
- People needed
- 28
- Starts
- 2005-12-26
- Expected to finish
- 2017-03-31
- Last updated by the study team
- 2023-03-13
Who can join
Age: any, up to 5. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Newly diagnosed Group B intraocular retinoblastoma meeting 1 of the following criteria:
- Group B tumor(s) in 1 eye
- Group B tumor(s) in both eyes
- Group A tumor in 1 eye and Group B tumor(s) in the other eye
- Group E tumor in 1 eye that has been enucleated and Group B tumor(s) in the remaining eye at the time of enucleation of the Group E tumor
- Defined by the International Classification System for Intraocular Retinoblastoma as follows:
- Group A: Small tumors (≤ 3 mm in greatest dimension) confined to the retina, away from foveola and disc meeting the following criteria:
- More than 3 mm from fovea
- More than 1.5 mm from optic disk
- Group B: Tumors more than 3 mm meeting the following criteria:
- Confined to the retina in any location not in Group A
- Tumor associated subretinal fluid < 3 mm from the tumor margin with no subretinal seeding
- Group E: Must have ≥ 1 of the following present:
- Tumor touching the lens
- Tumor anterior to anterior vitreous face involving ciliary body or anterior segment
- Diffuse infiltrating retinoblastoma
- Neovascular glaucoma
- Opaque media from hemorrhage
- Tumor necrosis with aseptic orbital cellulites
- Phthisis bulbi
- Confirmation of diagnosis by CT scan or MRI of the brain and orbits AND an ophthalmologic evaluation under anesthesia within the past 3 weeks
- No choroidal and/or optic nerve invasion past the lamina cribosa
- No evidence of extraocular retinoblastoma clinically or by head and orbital MRI and/or CT scan
- No tumor present on histological exam at the cut end of the optic nerve for any Group E eye enucleated before study entry
- Performance status - ECOG 0-2
Where it is running
- Children's Hospital Los Angeles — Los Angeles, California, United States
- Lurie Children's Hospital-Chicago — Chicago, Illinois, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Wayne State University/Karmanos Cancer Institute — Detroit, Michigan, United States
- Duke University Medical Center — Durham, North Carolina, United States
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- Children's Oncology Group — Philadelphia, Pennsylvania, United States
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas, United States
- Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.